Because the genetic backgrounds of the LSL-Kras; p53FL/FL and LSL-Kras; Ink4a/ARFFL/FL mice are not the same, we have not made a direct comparison of tumor response for each treatment across the two genotypes. This evidence concerns the gene KRAS and neoplasm.